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Background: The methylation of DNA is recognized as a key epigenetic mechanism and evidence for its role in the
development of several malignancies is accumulating. We evaluated the relationship between global methylation in
DNA derived from normal appearing colon mucosal tissue and blood leukocytes, and colorectal adenoma risk.
Methods: Patients, aged 40 to 65, scheduled for a screening colonoscopy were recruited. During the colonoscopy,
two pinch biopsies of healthy, normal appearing mucosa were obtained from the descending colon. A fasting
blood sample was also collected. The methylation status of LINE-1 (long interspersed nuclear element-1) repetitive
sequences, as a surrogate measure of global methylation, was quantified in DNA extracted from normal colon
mucosa and blood leukocytes. Statistical analysis of the relationship between global DNA methylation and adenoma
risk was conducted on 317 participants, 108 subjects with at least one pathologically confirmed adenoma and 209
subjects with a normal colonoscopy.
Results: A statistically significant inverse relationship was observed between LINE-1 methylation in colon tissue
DNA and adenoma risk for males and for both sexes combined for the lowest methylation quartile compared to
the highest (adjusted ORs = 2.94 and 2.26 respectively). For blood, although the overall pattern of odds ratio
estimates was towards an increase in risk for lower methylation quartiles compared to the highest methylation
quartile, there were no statistically significant relationships observed. A moderate correlation was found between
LINE-1 methylation levels measured in tissue and blood (Pearson correlation 0.36).
Conclusions: We observed that lower levels of LINE-1 DNA methylation in normal appearing background colon
mucosa were associated with increased adenoma risk for males, and for both sexes combined. Though these
findings provide some support for a relationship between LINE-1 DNA methylation in colon mucosal tissue and
adenoma risk, large prospective cohort studies are needed to confirm results. Until such investigations are done,
the clinical usefulness of LINE-1 methylation as a biomarker of increased adenoma risk is uncertain. Regardless, this
study contributes to a better understanding of the role of global DNA methylation as an early event in CR
carcinogenesis with implications for future etiologic research.
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There is wide-spread interest in clarifying the role of aber-
rant global DNA methylation as an early event in colorectal
carcinogenesis. Colorectal cancer, the third most commonly
diagnosed cancer worldwide, is associated with significant
mortality and morbidity [1-3]. Despite decreasing trends in* Correspondence: kingw@queensu.ca
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both males and females, colorectal cancer remains the sec-
ond most common cause of cancer death in Canada and
the United States for both sexes combined [4,5]. The clas-
sical model for colorectal tumour development involves a
stepwise histological progression from aberrant proliferative
epithelial dysplasia to adenoma (adenomatous polyp) to
colorectal cancer (adenocarcinoma) [6-9].
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the development of several malignancies is accumulating
[10-12]. Global DNA methylation refers to the overall
genome-wide content of methylated cytosines within
CpG (cytosine-phosphate-guanine) sites [13,14]. The
majority of CpG sites (about 80%) are found in repeti-
tive sequences, multiple copies of DNA that are normally
methylated [15]. LINE-1 (long interspersed nuclear
element-1) sequences, with an average size of 900 base
pairs, comprise approximately 17% of the human genome
[16] and are the most widely studied repetitive sequence
within the context of global DNA methylation measure-
ment [17,18]. LINE-1 methylation levels have been shown
to represent a reliable surrogate measure of global DNA
methylation [19-23].
Global DNA hypomethylation, which is characterized
by a generalized decrease in the number of methylated
cytosines within CpG sites, is recognized as an early and
consistent event in colorectal carcinogenesis [24-28] and
is associated with mechanisms that drive the early stages
of the carcinogenic process including chromosomal in-
stability [29-31], elevated chromosomal mutation rates
[32,33] and loss of imprinting [34-36]. Yamada et al. [28]
observed a significantly increased number of microadeno-
mas (small colonic intramucosal lesions) in hypomethy-
lated mouse models as compared to controls suggesting
that hypomethylation may promote early stage tumour de-
velopment in the colon in mice [28]. In humans, the role
of global DNA methylation in colorectal tumourigenesis
has primarily been investigated by comparing methylation
patterns in colorectal tumour tissue, with matched adja-
cent normal appearing tissue obtained from the same
patient [37-42] or with normal colon tissue from non-
diseased control subjects [37,38]. These studies indicate
that virtually all colorectal tumours (benign adenomas and
cancers) display a higher degree of reduction in methyl-
ated cytosines within CpG sites (global hypomethylation)
as compared to matched and unmatched normal appear-
ing colon tissue. However, from a carcinogenic mechanism
perspective, these study designs using tumour tissue are
limited with respect to distinguishing global hypomethyla-
tion occurring early in the dysplasia-adenoma sequence
that may drive tumour initiation, from methylation changes
occurring later in the adenoma-carcinoma sequence, or
those which may promote tumour progression or simply be
passengers in the process [43].
Contrary to this approach using tumour tissue, a study
design that compares global methylation patterns in nor-
mal colon mucosal biopsy tissue from colonoscopy pa-
tients with colorectal adenomas (as surrogate end points
for colorectal cancer) to participants without adenomas
has the potential to better elucidate the role of aberrant
global methylation as a potential marker of the early stages
of colorectal adenoma/cancer etiology. Only two smallprevious observational studies by Cravo et al. [44] (N = 12
adenoma, N = 8 normal colonoscopy) and Pufulete et al.
[45] (N = 35 adenoma, N = 76 normal colonoscopy) have
examined the relationship between global methylation
levels and colorectal adenoma using this type of study de-
sign [44,45]. Results indicating lower global methylation
levels in normal appearing healthy colorectal mucosa of
patients with colorectal adenomas [44,45] as compared to
patients without colorectal pathology support the premise
that aberrant global hypomethylation may represent a per-
vasive ‘field’ change throughout the colorectal mucosa that
may precede and/or initiate the development of colorectal
neoplasia/adenoma [40,42,46].
To better understand the role of aberrant global DNA
methylation in the earliest stages of colorectal tumouri-
genesis (adenoma development) at the population level,
further assessment of the association between global
methylation and adenoma risk is warranted. To this end,
we evaluated the relationship between LINE-1 methyla-
tion levels (as a surrogate measure of global methyla-
tion) in normal appearing colon mucosal tissue samples
and adenoma risk within a large healthy screening colon-
oscopy patient population. We hypothesized that aberrant
global methylation in normal appearing colon mucosa
would reflect an underlying predisposition to the develop-
ment of colorectal adenomas and therefore, global DNA
hypomethylation would be associated with an increased
risk of adenomas. We also investigated the association be-
tween LINE-1 methylation levels measured in blood leu-
kocytes and adenoma risk as a secondary objective.
Methods
Study population
Patients aged 40 to 65 scheduled for a screening colonos-
copy at a regional endoscopy centre at Hotel Dieu Hos-
pital in Kingston, Ontario, between 2009 and 2012 were
recruited by mail approximately 1–4 months prior to their
colonoscopic procedure. Indications for colonoscopy in-
cluded a positive family history of colorectal adenoma or
cancer in a first or second degree relative, a positive fecal
occult blood test (FOBT) result and average risk screening.
Patients with previously diagnosed inflammatory bowel
disease (IBD -ulcerative colitis or Crohn’s disease), and pa-
tients with a known history of genetic disorders that pre-
dispose to colorectal cancer (hereditary nonpolyposis
colorectal cancer, familial adenomatous polyposis) were
not recruited for this study. Subjects with any GI abnor-
mality (adenoma, hyperplastic polyp or cancer) detected at
a previous colonoscopy or with a new diagnosis, recur-
rence or treatment of any cancer type (except non-
melanoma skin cancer) in the 5 years prior to colonoscopy
were also not invited to participate in the study. In
addition, those diagnosed with IBD or colorectal cancer
based on current colonoscopy findings were excluded
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global DNA methylation levels in these patients may not
be consistent with the target time period of interest (pre-
adenoma development). In order to define a homogeneous
adenoma outcome group, patients with serrated aden-
omas, sessile serrated adenomas or only hyperplastic
polyp(s), were not included in the analysis.
At the colonoscopy visit, a fasting venous blood sample
was collected in an EDTA (ethylenediaminetetraacetic acid)
vacutainer which was immediately placed on ice, and centri-
fuged within 45 minutes of the blood draw. The buffy layer
(blood leukocytes) was removed and stored at -20ºC until
DNA extraction. During the colonoscopy, in an attempt to
represent overall methylation levels in the descending colon,
two pinch biopsies of healthy, normal appearing mucosa
were obtained from the descending colon, 10 cm apart, and
at least 10 cm away from any lesion, polyp or other mucosal
abnormality. Specimens were immediately placed in cell lysis
solution (5-PRIME DNA Isolation kit, Inter Medico, Mark-
ham, ON, Canada) and stored at -20°C.
Laboratory methods
DNA was extracted from colon mucosal tissue biopsies
and blood leukocytes using the 5-PRIME DNA isolation
kit (Inter Medico, Markham, ON, Canada) according to
instructions provided by the manufacturer and purified
DNA was stored at −20°C until use. High-resolution
melting (HRM) profile analysis, a real-time florescence-
based polymerase chain reaction method, was used to
measure methylation status of LINE-1 repetitive se-
quences, as a surrogate measure of global DNA methy-
lation, in DNA extracted from each colon tissue sample
and blood leukocytes. The application and validation of
HRM to the measurement of LINE-1 DNA methylation
has been described in detail previously [47]. Briefly,
prior to HRM, DNA was bisulfite-converted leading to a
primary sequence change in the DNA that permits differ-
entiation of unmethylated cytosines from 5-methyl-
cytosine [48]. Primers were designed to target the LINE-1
consensus promoter region, from which 8 representative
CpG sites of interest, previously validated as representative
of global DNA methylation status, were selected for HRM
profile analysis [20]. A LINE-1 loci-specific percent meth-
ylated value for this representative sub-set of CpG sites
was obtained by comparing melting curves of participant
bisulfite-converted DNA to a set of standard DNA refer-
ence controls with known levels of unmethylated and
methylated cytosines. LINE-1 methylation analysis was
carried out in triplicate for bisulfite-converted DNA from
each of the two tissue DNA samples and from blood leu-
kocytes on 96-well plates. Each plate also included a no-
template control, a set of reference methylation standards,
and three replicates of internal control peripheral blood
DNA to allow for assessment of inter-assay variability.Triplicate measures of LINE-1 methylation were obtained
for each of the two tissue DNA samples and blood
leukocyte DNA. Individual triplicate measures were ex-
cluded where PCR values were not satisfactory due to a
high PCR threshold crossing point (Cp value > 27). In
addition, individual outliers (defined as >10% difference
from each of the remaining triplicate values) were excluded
from the analysis [47]. Average tissue and blood leukocyte
percent methylation values for each individual subject were
calculated by averaging all remaining triplicates for the two
tissue DNA samples and averaging the remaining triplicates
for the blood DNA samples respectively.
Statistical analysis
To determine whether LINE-1 methylation levels in
colon tissue or blood leukocyte DNA differ between pa-
tients with and without adenomas, outcome status was
defined as follows: Study subjects with no abnormality de-
tected at colonoscopy were assigned to the ‘normal colon-
oscopy’ group. Any abnormal tissue removed during
colonoscopy was assessed by an expert gastrointestinal
pathologist using standard histologic criteria as per hos-
pital procedures. Using standard diagnostic criteria, sub-
jects with one or more pathologically-confirmed tubular,
tubulo-villous or villous adenoma(s) comprised the aden-
oma group.
Overall average LINE-1 methylation levels for colon tis-
sue and blood leukocyte DNA were categorized into quar-
tiles based on sex-specific distributions among participants
with a normal colonoscopy. Adenoma risk was also exam-
ined using a continuous representation of sex-specific stan-
dardized LINE-1 methylation measures. These analyses
were conducted separately for males and females, and for
both sexes combined. Unconditional logistic regression was
performed to estimate odds ratios (OR) and 95% confi-
dence intervals (CI) as measures of association controlling
for age. Sex-specific methylation measures negated the ne-
cessity to further control for sex and other risk factors for
adenoma were not considered as potential covariates as
they were hypothesized to be on the causal pathway. The
odds ratio provides a measure of direction, strength and
statistical significance of the relationships of interest – but
does not estimate the prevalence ratio in this study sample.
Institutional ethics approval was obtained from the
Queen’s University Health Sciences and Affiliated Teaching
Hospitals Research Ethics Board (File No. 6004521) and all
subjects provided informed consent.
Results
Of the 728 subjects who met the initial eligibility criteria
and were mailed recruitment packages, 444 consented to
participate in the study (61% response rate). A further 48
subjects were excluded due to colonoscopy scheduling
problems, or because the colonoscopy was incomplete
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tending clinician did not obtain the two healthy tissue
biopsies. Of the 396 remaining subjects, 66 were excluded
on the basis of an ineligible diagnosis resulting from the
colonoscopy (IBD, colorectal cancer, serrated adenoma,
sessile serrated adenoma or hyperplastic polyps) leaving
330 subjects eligible for tissue and blood methylation
measurement. DNA methylation was successfully mea-
sured in tissue for 317 subjects, and of these, 280 also had
blood methylation measures. Pathology results for the tis-
sue methylation analysis (n = 317) identified 108 partici-
pants with at least one adenoma (101 with tubular
adenomas and 7 with tubulo-villous adenomas) and 209
subjects with a normal colonoscopy.
HRM was performed in triplicate on DNA isolated
from each tissue and blood sample. The intra-assay coef-
ficient of variation within tissue and blood triplicates
was 1.84% and 1.81% respectively. An internal control
sample was included on each of the 37 plates and the
inter-assay coefficient of variation was 0.89%. Two colon
tissue samples with completed methylation measures
were available for 262 participants (Pearson correlation
between the averages of the two tissue samples = 0.66)
and methylation values were available for one tissue
sample for the remaining 55 study subjects.
The primary indication for colonoscopy in our patient
population was a positive family history for colorectal
cancer or colorectal adenoma (Table 1). Those undergo-
ing a colonoscopy because of a positive fecal occult
blood test (FOBT) were more likely to be diagnosed with
adenoma than the positive family history group. Males
were more often diagnosed with adenoma as compared
to females (53% versus 20% respectively).
LINE-1 methylation values in tissue were approximately
normally distributed within males, females and both sexes
combined. Table 2 presents the relationship between quar-
tiles of LINE-1 DNA tissue methylation and adenoma risk
for males, females, and both sexes combined. The highest
quartile of LINE-1 methylation was used as the referent for
odds ratio estimates. ORs (adjusted for age) were larger for
males as compared to females, but not statistically different
(p-value interaction = 0.65). Males in the lowest quartile
had a statistically significant elevation in adenoma risk (age
adjusted OR 2.94, 95% CI: 1.02-8.47). For both sexes com-
bined, there was a pattern of increasing ORs from high to
low methylation quartiles, and a statistically significant in-
crease in adenoma risk for those in the lowest quartile (age
and sex adjusted OR= 2.26, 95% CI: 1.11-4.58).
Methylation values in blood were available for 280 pa-
tients (185 normal colonoscopies and 95 adenomas). A
moderate correlation was observed between blood and tis-
sue methylation values (Pearson correlation 0.36). Al-
though the overall pattern of odds ratio estimates was
towards an increase in risk for lower methylation quartilesin blood leukocytes compared to the highest methylation
quartile (referent), there were no statistically significant re-
lationships observed (Table 3).
Results for continuous representations of sex-specific
standardized LINE-1 methylation levels in colon tissue
or blood leukocytes showed no relationships with aden-
oma (see Table 2 and Table 3). Findings were unaffected
for all analyses (tissue and blood) when the study popu-
lation was restricted to subjects with a positive family
history of CRC or adenoma in a first or second degree
relative (data not shown).
Discussion
This cross-sectional study utilized a healthy screening
colonoscopy population to assess the relationship be-
tween LINE-1 methylation levels measured in normal
appearing background colon tissue DNA (as a surrogate
for global methylation), and colorectal adenoma risk.
Overall, our results support a relationship between glo-
bal DNA hypomethylation in normal appearing back-
ground colon mucosa and increased colorectal adenoma
risk. A statistically significant inverse relationship was
observed between LINE-1 methylation in tissue DNA
and adenoma risk for males and for both sexes com-
bined for the lowest methylation quartile compared to
the highest (adjusted ORs = 2.94 and 2.26 respectively).
The overall pattern of effects was consistent with an in-
creased risk of adenoma for subjects in the lower methy-
lation quartiles in comparison to those with the highest
levels of methylation.
The results of our study, which is the largest study pub-
lished to date that evaluated the relationship between glo-
bal methylation and colorectal adenoma development by
comparing LINE-1 DNA methylation levels in normal
appearing colon tissue biopsies between colonoscopy pa-
tients with and without adenomas, are generally consistent
with two previous smaller observational studies that
assessed this relationship (studies included 12 and 35 ad-
enoma cases respectively) [44,45]. Our study improved
upon these two studies by including a larger number of
participants recruited from a clinically relevant healthy
screening population. In addition, our results are in keep-
ing with Belshaw et al. [49], who reported significantly
lower LINE-1 methylation levels in colonic crypts isolated
from morphologically normal colorectal mucosa from
colorectal cancer patients as compared to subjects with no
known gastrointestinal pathology [49].
Given that colorectal adenomas are more common in
males as compared to females [50,51], that sex-specific
differences in risk factors for colorectal tumours have
been reported [52,53], and that many studies have found
that LINE-1 methylation levels are higher in males [54],
assessing the relationship between LINE-1 methylation
levels and adenoma risk stratified by gender is important
Table 1 Description of patient population
Normal Adenoma
n (%) n (%) Odds ratio (95% CI)
Indication for colonoscopy
Positive family history* 171 (71%) 70 (29%) 1.00 referent
Positive FOBT** 33 (51%) 32 (49%) 2.37 (1.35-4.15)
Average risk screening 5 (45%) 6 (55%) 2.93 (0.87-9.92)
Sex
Female 144 (80%) 36 (20%) 1.00 referent
Male 65 (47%) 72 (53%) 4.43 (2.70-7.28)
Age
40-49 39 (71%) 16 (29%) 1.00 referent
50-54 65 (66%) 33 (34%) 1.24 (0.60-2.54)
55-59 56 (65%) 30 (35%) 1.31 (0.63-2.71)
60-65 49 (63%) 29 (37%) 1.44 (0.69-3.03)
*Positive family history of cancer or adenoma.
**Positive fecal occult blood test.
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tion in CRC etiology [55]. To the best of our knowledge,
this is the first study to report sex-specific relationships
within the context of colorectal adenoma/cancer risk,
though differences in bladder cancer risk for males and




N (%) N (%)
Both sexes***
1 Low 52 (60%) 35 (40%)
2 53 (63%) 31 (37%)
3 51 (66%) 26 (34%)
4 High 53 (77%) 16 (23%)
Standardized continuous
Males
1 (79.87 - 87.42) 16 (42%) 22 (58%)
2 (87.43 - 89.55) 17 (44%) 22 (46%)
3 (89.56 - 92.06) 15 (44%) 19 (56%)
4 (92.07 - 95.94) 17 (65%) 9 (35%)
Standardized continuous
Females
1 (75.13 - 85.59) 36 (73%) 13 (27%)
2 (85.60 - 87.86) 36 (80%) 9 (20%
3 (87.87 - 89.95) 36 (84%) 7 (16%)
4 (89.96 - 97.95) 36 (84%) 7 (16%)
Standardized continuous
*Odds ratios are adjusted for age (continuous).
**Age adjusted Wald chi square p-value.
***LINE-1 methylation quartiles based on sex-specific quartiles.indicating a relationship between global/LINE-1 hypo-
methylation and increased adenoma risk for males but not
females suggest that aberrant global DNA methylation
patterns in males may play a more significant role in early
CR tumour development as compared to females. How-
ever, sex-specific results should be interpreted with someal colon tissue biopsies and adenoma risk (n = 317)
Adjusted*
OR (95% CI) OR 95% (CI) p-value**
2.23 (1.10-4.51) 2.26 (1.11-4.58) 0.02
1.94 (0.95-3.95) 2.01 (0.98-4.11) 0.06
1.69 (0.81-3.51) 1.68 (0.80-3.50) 0.17
1.00 referent 1.00 referent
0.87 (0.69-1.10) 0.85 (0.68-1.08) 0.19
2.60 (0.92-7.30) 2.94 (1.02-8.47) 0.05
2.44 (0.88-6.82) 2.85 (0.99-8.18) 0.05
2.39 (0.83-6.87) 2.52 (0.87-7.32) 0.09
1.00 referent 1.00 referent
0.84 (0.60-1.81) 0.80 (0.56-1.14) 0.21
1.86 (0.66-5.19) 1.80 (0.64-5.05) 0.26
1.29 (0.43-3.83) 1.27 (0.43-3.79) 0.67
1.00 (0.32-3.14) 0.98 (0.31-3.07) 0.97
1.00 referent 1.00 referent
0.87 (0.60-1.25) 0.87 (0.60-1.25) 0.44




N (%) N (%) OR (95% CI) OR 95% (CI) p-value**
Both sexes***
1 Low 47 (64%) 26 (36%) 1.38 (0.67-2.86) 1.39 (0.67-2.89) 0.37
2 45 (61%) 29 (39%) 1.61 (0.79-3.31) 1.67 (0.81-3.44) 0.17
3 48 (69%) 22 (31%) 1.15 (0.55-2.41) 1.13 (0.54-2.39) 0.75
4 High 45 (71%) 18 (29%) 1.00 referent 1.00 referent
Standardized continuous 0.85 (0.66-1.09) 0.83 (0.65-1.07) 0.15
Males
1 (79.87 - 87.42) 15 (45%) 18 (55%) 1.40 (0.50-3.93) 1.38 (0.49-3.89) 0.54
2 (87.43 - 89.55) 14 (39%) 22 (61%) 1.83 (0.66-5.09) 1.85 (0.67-5.17) 0.24
3 (89.56 - 92.06) 15 (52%) 14 (48%) 1.09 (0.38-3.15) 1.06 (0.37-3.08) 0.92
4 (92.07 - 95.94) 14 (54%) 12 (46%) 1.00 referent 1.00 referent
Standardized continuous 0.72 (0.47-1.09) 0.71 (0.47-1.08) 0.11
Females
1 (75.13 - 85.59) 32 (80%) 8 (20%) 1.29 (0.40-4.15) 1.36 (0.42-4.44) 0.61
2 (85.60 - 87.86) 31 (82%) 7 (18%) 1.17 (0.35-3.87) 1.27 (0.38-4.29) 0.70
3 (87.87 - 89.95) 33 (80%) 8 (20%) 1.25 (0.39-4.02) 1.28 (0.39-4.16) 0.68
4 (89.96 - 97.95) 31 (64%) 6 (16%) 1.00 referent 1.00 referent
Standardized continuous 0.94 (0.63-1.41) 0.91 (0.61-1.38) 0.66
*Odds ratios are adjusted for age (continuous).
**Age adjusted Wald chi square p-value.
***LINE-1 methylation quartiles based on sex-specific quartiles.
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female-specific analysis.
Though our results were consistent with an elevated risk
of adenoma associated with lower blood leukocyte methy-
lation quartiles compared to the highest methylation quar-
tile for all subjects combined and sex-specific analyses, no
statistically significant relationships were observed be-
tween LINE-1 methylation levels in blood leukocytes and
adenoma risk. These results are in contrast with two pre-
vious studies that both reported an increased risk of aden-
oma associated with lower global methylation levels
measured in blood leukocytes [45,58].
We observed only a moderate correlation between
LINE-1 methylation levels measured in colon tissue and
blood leukocytes which may explain the null results for
blood LINE-1 methylation and adenoma risk. In addition,
fewer subject were available for the blood leukocyte ana-
lysis and statistical power to detect associations was there-
fore limited. Our non-significant findings together with
only a moderate correlation between colon tissue and
blood leukocyte LINE-1 methylation have important im-
plications for planning future epidemiologic investigations
of methylation markers and colorectal cancer/adenoma
risk, when, due to practical considerations, only blood or
other accessible sources of DNA are available for methyla-
tion analysis [59].This clinic-based study utilizing a biologic marker of in-
creased risk avoids or limits many traditional biases of ob-
servational studies. In particular, information bias is unlikely
as this study relied on blinded methylation analysis of tissue
samples and pathology reports to assess exposure and out-
come respectively. Although our study population is not
representative of the overall general population (due to the
colonoscopy clinic-based recruitment and response rates),
this is less of a concern given that our sample represents a
relevant sub-group of referrals to a regional colonoscopy
screening program and also, since the study objectives are
oriented towards understanding a biologic relationship pos-
tulated to be consistent irrespective of the population stud-
ied. In addition, traditional risk factors are thought to be
upstream of DNA methylation (on the causal pathway) such
that control for confounding is not a concern.
This study relied on cross-sectional exposure and outcome
measures, and was therefore subject to the classical limita-
tions of cross-sectional design with respect to temporality,
prevalent events, and representation of exposure windows.
However, each of these limitations was mitigated to some
degree by the examination of exposure (LINE-1 methylation)
and outcome (adenoma) that are themselves intermediate
events in a causal chain, with a shorter temporal scale than
exposure-cancer relationships. However, reverse causality, re-
mains a potential explanation for the relationship observed.
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(adenoma) and exposure (LINE-1 methylation) may have
biased our results towards the null. The ‘miss rate’ of col-
onoscopy for adenomas has been reported to be from 6-
12% for adenomas one centimetre or larger and up to 25%
for adenomas less than one centimetre in diameter [60].
For our study, it is expected that the rate of missed aden-
omas is of less concern as all colonoscopies were per-
formed at a single clinical centre by experienced academic
gastroenterologists who each perform more than 200 col-
onoscopies per year and participate in an ongoing quality
control program with specific audited goals for polyp de-
tection and cecal intubation rates [61,62].
Our cross-sectional measure of global DNA methyla-
tion is intended to represent LINE-1 methylation levels
prior to the initiation of the dysplasia-adenoma se-
quence. Although there is some evidence of stability of
global methylation levels within individuals over time
[63], there is likely a degree of misclassification due to
this assumption. We focused on LINE-1 repetitive ele-
ments in the genome that are often intensively methyl-
ated as a proxy for global DNA methylation. Although
LINE-1 methylation is strongly correlated with genomic
instability, [31,64-66] non-differential misclassification of
methylation status due to this proxy measure could have
attenuated observed effects in this study. Also, the cor-
relation of 0.66 between methylation levels of the two
colon tissue samples indicates some heterogeneity of
LINE-1 methylation status in the descending colon and
suggests that our results may not be generalizable to tis-
sue biopsies taken from other parts of the colon.
Conclusions
The study of biomarkers for increased risk of colorectal
cancer has enormous potential for understanding colo-
rectal cancer etiology. Our results indicating that LINE-
1 DNA hypomethylation in normal appearing colon mu-
cosa is associated with increased adenoma risk, suggest
that aberrant global hypomethylation in healthy back-
ground colon mucosa represents an underlying pervasive
epigenetic aberration, often referred to as a ‘field defect’,
which may confer an increased predisposition to the de-
velopment of colorectal adenomas/cancer [46,67-70].
Though these findings provide some support for a rela-
tionship between LINE-1 DNA methylation in colorectal
mucosal tissue and adenoma risk, large prospective co-
hort studies are needed to confirm results. Until such in-
vestigations are done, the usefulness of this measure of
LINE-1 methylation in colon tissue (or blood leukocyte)
DNA as a biomarker of increased adenoma risk that can
be used in clinical settings is uncertain. However, even
though the clinical significance of our findings is unclear,
this study contributes to a better understanding of the
role of global DNA methylation in colorectal tissue as anearly event in CR carcinogenesis with implications for
future CRC etiologic research investigating suspected
environmental and lifestyle risk factors using global
DNA hypomethylation as an informative end point.
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